Skip to content

Bausch + Lomb BLCO Noncontrolling interests in subsidiaries

Noncontrolling interests in subsidiaries at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
-$558K-67.6%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$34M-42.4%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
AbbVie logo
AbbVieABBV
Pfizer logo
PfizerPFE
Merck & Co. logo
Merck & Co.MRK

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%
Free cash flow-$68.0M+49.6%

Valuation

See full
Market cap$5.43B+10.2%

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's noncontrolling interests in subsidiaries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's noncontrolling interests in subsidiaries?
Bausch + Lomb (BLCO) reported noncontrolling interests in subsidiaries of $73M in Q1 2026.
How has Bausch + Lomb's noncontrolling interests in subsidiaries changed year-over-year?
Bausch + Lomb's noncontrolling interests in subsidiaries increased by 1.4% year-over-year, from $72M to $73M.
What is the long-term trend for Bausch + Lomb's noncontrolling interests in subsidiaries?
Over 4 years (2021 to 2025), Bausch + Lomb's noncontrolling interests in subsidiaries has grown at a -0.7% compound annual growth rate (CAGR), from $73M to $71M.
What does noncontrolling interests in subsidiaries mean?
This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.